Prothya Biosolutions isolates proteins from blood plasma to produce plasma-derived medicinal products for immunology and critical care. This technology addresses the need for life-saving therapies for patients who rely on essential plasma-derived medicines.
Funding
$105.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients requiring specialized treatments for immunological disorders and critical care often depend on plasma-derived medicinal products, which can face supply constraints and complex manufacturing processes. The availability of these life-saving therapies is crucial for individuals with specific medical needs.
Solution
Prothya Biosolutions specializes in isolating proteins from blood plasma to manufacture plasma-derived medicinal products, ensuring a consistent supply of these essential therapies for immunology and critical care. Utilizing advanced methods and a long legacy of expertise, Prothya provides healthcare organizations worldwide with high-quality services and products. By focusing on both its own branded products and collaborative partnerships, Prothya aims to create value for its partners and contribute to sustaining the health of patients who rely on these specialized medicines.
Target Audience
The primary audience includes healthcare-oriented organizations, healthcare professionals, and patients who depend on plasma-derived medicinal products for immunology and critical care.
Features
- Advanced protein isolation techniques from blood plasma
- Manufacturing of plasma-derived medicinal products for immunology
- Production of plasma-derived medicinal products for critical care
- CDMO (Contract Development and Manufacturing Organization) services for partners
- Focus on high-quality services and products